Abstract
Baroreflex activation therapy (BAT) results in centrally mediated reduction of sympathetic outflow and increased parasympathetic activity to the heart via a physiological reflex pathway. In a pilot study in 11 NYHA Class III heart failure (HF) patients, BAT produced a persistent significant reduction of sympathetic activity over 21 months follow-up and a dramatic decrease in the number and length of hospitalizations. In a multinational, prospective, randomized, parallel-controlled, clinical trial in 146 NYHA Class III HF patients, BAT produced a significant N-terminal pro-brain natriuretic peptide reduction (p <0.02). This was associated with a trend toward fewer in-hospital days for HF. BAT might become a powerful tool to repair autonomic alterations due to HF at their origin and thus, profoundly affect the prognosis of advanced HF patients.
Original language | English |
---|---|
Pages (from-to) | 559-569 |
Number of pages | 11 |
Journal | Interventional Cardiology |
Volume | 7 |
Issue number | 6 |
DOIs | |
Publication status | Published - Dec 1 2015 |
Keywords
- Autonomic nervous system
- Baroreflex
- Heart failure
- Nonpharmacologic therapy
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine